Quisel John D 4

What Happened

• John D. Quisel, a director of Gossamer Bio (GOSS), was granted a derivative award of 115,000 shares reported as Code A (award/acquisition) on 2026-06-04. The report lists an acquisition price of $0.00 (i.e., a grant of a derivative instrument rather than an open-market purchase), so no cash was paid by the insider at grant.

Key Details

• Transaction date: 2026-06-04; Form 4 filed: 2026-06-05 (timely).
• Reported grant: 115,000 shares @ $0.00 (derivative award, Code A).
• Footnote F1: Award made pursuant to the company’s Non-Employee Director Compensation Program.
• Footnote F2: The entire number of shares subject to this option becomes fully vested and exercisable on the earlier of (a) the first anniversary of the grant date or (b) the next annual meeting, subject to continued board service.
• Shares owned after the transaction: not specified in the provided filing.

Context

• This appears to be an option-style director award (a common form of non-employee director compensation). As a derivative grant, Quisel does not receive tradable shares immediately — vesting and exercise will be required before he can own or sell stock.
• Such director awards are routine corporate compensation and should not be interpreted alone as a buy/sell signal; purchases (open-market buys) typically carry more direct informational value for investors.